Uncommon occurrence of fluoroquinolone resistance-associated alterations in GyrA and ParC in clinical strains of Chlamydia trachomatis
References (26)
Mechanisms of quinolone resistance
J Infect Chemother
(1997)- et al.
In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV
J Urol
(2000) Centers for Disease Control and Prevention Guidelines for treatment of sexually transmitted diseases 2002
Morb Mortal Wkly Rep
(2002)- et al.
Practical recommendations for the drug treatment of bacterial infections of the male genital tract including urethritis epididymitis and prostatitis
Drugs
(1999) Japanese Society for Sexually Transmitted Diseases
Guidelines for the diagnosis and treatment of sexually transmitted diseases. Jpn J Sex Transm Dis
(1999)- et al.
Tetracycline-resistant Chlamydia trachomatis in Toulouse France
Pathol Biol (Paris)
(1997) - et al.
Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure
J Infect Dis
(2000) - et al.
Sequencing of gyrase and topoisomerase IV quinoloneresistance- determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained in vitro
Antimicrob Agents Chemother
(1998) - et al.
Serial passage of Chlamydia spp In sub-inhibitory fluoroquinolone concentrations
J Antimicrob Chemother
(2002) - et al.
Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli
Antimicrob Agents Chemother
(1990)
Isolation of Chlamydia trachomatis from patients with urethritis
Kansenshogaku Zasshi
(1984)
Phylogeny-based rapid identification of mycoplasmas and ureaplasmas from urethritis patients
J Clin Microbiol
(2002)
Cited by (18)
Macrolide and fluoroquinolone resistance is uncommon in clinical strains of Chlamydia trachomatis
2018, Journal of Infection and ChemotherapyCitation Excerpt :However, we did find V61A and H129Q in GyrA in 44 specimens. In our previous study [19], we reported some amino acid changes, including V61A, in GyrA in 7 clinical isolates of C. trachomatis from male NGU, but we did not find any amino acid changes within the QRDRs of the gyrA gene in 23 clinical isolates. In two previous studies [20,21], the reference strains of C. trachomatis L2, which is a pathogen of lymphogranuloma venereum, were exposed to fluoroquinolones serially in vitro.
In vitro antichlamydial activity of garenoxacin against Chlamydia trachomatis
2012, Journal of Infection and ChemotherapyClinical and microbiological outcomes in treatment of men with non-gonococcal urethritis with a 100-mg twice-daily dose regimen of sitafloxacin
2012, Journal of Infection and ChemotherapyResistance of different Chlamydia-like organisms to quinolones and mutations in the quinoline resistance-determining region of the DNA gyrase A- and topoisomerase-encoding genes
2006, International Journal of Antimicrobial AgentsExtra Virgin Olive Oil-Based Formulations: A “Green” Strategy against Chlamydia trachomatis
2023, International Journal of Molecular Sciences
Copyright © 2004 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.